| 2020-12-01 | AstraZeneca AB | $1,634 | Research payment | Cash or cash equivalent | FASENRA Drug, Respiratory | A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. | 2020 |
| 2020-11-10 | Partner Therapeutics, Inc. | $10,000 | Research payment | Cash or cash equivalent | Leukine Drug, Hematology | iLEUKPULM | 2020 |
| 2020-11-02 | Partner Therapeutics, Inc. | $778 | Research payment | In-kind items and services | LEUKINE Drug, Hematology | ILeukPulm | 2020 |
| 2020-10-28 | Novartis Pharmaceuticals Corporation | $15,747 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | PROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF) | 2020 |
| 2020-10-23 | Partner Therapeutics, Inc. | $32 | Research payment | In-kind items and services | LEUKINE Drug, Hematology | ILeukPulm | 2020 |
| 2020-10-20 | Partner Therapeutics, Inc. | $15,420 | Research payment | Cash or cash equivalent | Leukine Drug, Hematology | iLEUKPULM | 2020 |
| 2020-10-20 | Partner Therapeutics, Inc. | $2,009 | Research payment | In-kind items and services | LEUKINE Drug, Hematology | ILeukPulm | 2020 |
| 2020-10-15 | American Regent | $1,600 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2020 |
| 2020-10-08 | Vifor (International) Ltd. | $7,500 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2020 |
| 2020-10-08 | Vifor (International) Ltd. | $5,000 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2020 |
| 2020-10-08 | Vifor (International) Ltd. | $955 | Research payment | Cash or cash equivalent | Veltassa Drug, Potassium Binder | PAT-CR-302 | 2020 |
| 2020-09-08 | LEICA MICROSYSTEMS INC. | $271 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | | 2020 |
| 2020-09-08 | LEICA MICROSYSTEMS INC. | $271 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | | 2020 |
| 2020-09-08 | LEICA MICROSYSTEMS INC. | $271 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | | 2020 |
| 2020-09-01 | ABBVIE INC. | $587 | Research payment | Cash or cash equivalent | RINVOQ Drug, IMMUNOLOGY | M14-675 | 2020 |
| 2020-07-28 | CSL Behring | $514 | Research payment | In-kind items and services | | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 |
| 2020-07-21 | GE HEALTHCARE | $28,515 | Charitable Contribution | Cash or cash equivalent | | | 2020 |
| 2020-07-21 | GE HEALTHCARE | $2,300 | Charitable Contribution | Cash or cash equivalent | | | 2020 |
| 2020-06-25 | CSL Behring | $525 | Research payment | In-kind items and services | | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2020 |
| 2020-04-08 | American Regent | $300 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2020 |
| 2020-03-29 | Olympus America Inc. | $873 | Gift | In-kind items and services | Generator G400 Device, Energy | | 2020 |
| 2020-03-03 | Mallinckrodt Hospital Products Inc. | $11,772 | Research payment | Cash or cash equivalent | OFIRMEV Drug, ACUTE CARE | RANDOMIZED CONTROL TRIAL OF INTRAVENOUS ACETAMINOPHEN (OFIRMEV) FOR THE REDUCTION OF INTRAPARTUM MATERNAL FEVER AND FETA | 2020 |
| 2020-01-28 | LEICA MICROSYSTEMS INC. | $112 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | | 2020 |
| 2020-01-23 | LEICA MICROSYSTEMS INC. | $145 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | | 2020 |
| 2020-01-13 | American Regent | $6,850 | Research payment | Cash or cash equivalent | INJECTAFER Drug, Anemia | Heart_FID | 2020 |
| 2020-01-13 | LEICA MICROSYSTEMS INC. | $1,241 | Gift | Cash or cash equivalent | N/A Device, CANCER DIAGNOSTICS | | 2020 |
| 2020-01-10 | ABBVIE INC. | $300 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | SYNTHROID Drug, IMMUNOLOGY | | 2020 |
Comments